Effects of depression and melatonergic antidepressant treatment alone and in combination with sedative–hypnotics on heart rate variability: Implications for cardiovascular risk

World Journal of Biological Psychiatry

Volumn 19, Issue 5, 2018, Pages 368-378

  Chang, Chuan Chia ^a   Tzeng, Nian Sheng ^a,b   Yeh, Chin Bin ^a   Kuo, Terry B J ^c   Huang, San Yuan ^a   Chang, Hsin An ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

agomelatine; antidepressant; heart rate variability; Major depressive disorder; sedative hypnotics

Indexed keywords

AGOMELATINE; ALPRAZOLAM; BROMAZEPAM; BROTIZOLAM; CLONAZEPAM; ESTAZOLAM; FLURAZEPAM; HYPNOTIC SEDATIVE AGENT; LORAZEPAM; MIDAZOLAM; ZOLPIDEM; ZOPICLONE; ACETAMIDE DERIVATIVE; ANTIDEPRESSANT AGENT;

ADULT; AGE; ANXIETY; ARTICLE; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; FREQUENCY; HEART RATE VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONOTHERAPY; PATIENT; RR INTERVAL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; AUTONOMIC NERVOUS SYSTEM; COMBINATION DRUG THERAPY; DRUG EFFECT; HEART RATE; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; YOUNG ADULT;

ACETAMIDES; ADULT; ANTIDEPRESSIVE AGENTS; AUTONOMIC NERVOUS SYSTEM; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; FEMALE; HEART RATE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); YOUNG ADULT;

EID: 85014746734     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.1080/15622975.2017.1294765     Document Type: Article

References (63)

1. Agelink MW, Majewski TB, Andrich J, Mueck-Weymann M., 2002. Short-term effects of intravenous benzodiazepines on autonomic neurocardiac regulation in humans: a comparison between midazolam, diazepam, and lorazepam. Crit Care Med. 30:997–1006.
2. Baker B, Khaykin Y, Devins G, Dorian P, Shapiro C, Newman D., 2003. Correlates of therapeutic response in panic disorder presenting with palpitations: heart rate variability, sleep, and placebo effect. Can J Psychiatry. 48:381–387.
3. Barth J, Schumacher M, Herrmann-Lingen C., 2004. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med. 66:802–813.
4. Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Moller HJ., World Federation of Societies of Biological Psychiatry. Task Force on Unipolar Depressive D. 2013. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 14:334–385.
5. Berger S, Kliem A, Yeragani V, Bar KJ., 2012. Cardio-respiratory coupling in untreated patients with major depression. J Affect Disord. 139:166–171.
6. Bigger JT, Jr, Kleiger RE, Fleiss JL, Rolnitzky LM, Steinman RC, Miller JP., 1988. Components of heart rate variability measured during healing of acute myocardial infarction. Am J Cardiol. 61:208–215.
7. Bouairi E, Kamendi H, Wang X, Gorini C, Mendelowitz D., 2006. Multiple types of GABAA receptors mediate inhibition in brain stem parasympathetic cardiac neurons in the nucleus ambiguus. J Neurophysiol. 96:3266–3272.
8. Chalmers JA, Quintana DS, Abbott MJ, Kemp AH., 2014. Anxiety disorders are associated with reduced heart rate variability: a meta-analysis. Front Psychiatry. 5:80.
9. Chang HA, Chang CC, Kuo TB, Huang SY., 2015. Distinguishing bipolar II depression from unipolar major depressive disorder: differences in heart rate variability. World J Biol Psychiatry. 16:351–360.
10. Chang JS, Ha K, Yoon IY, Yoo CS, Yi SH, Her JY, Ha TH, Park T., 2012. Patterns of cardiorespiratory coordination in young women with recurrent major depressive disorder treated with escitalopram or venlafaxine. Prog Neuropsychopharmacol Biol Psychiatry. 39:136–142.
11. Cohen J., 1992. Statistical power analysis. Curr Dir Psychol Sci. 1:98–101.
12. Compton WM, Conway KP, Stinson FS, Grant BF., 2006. Changes in the prevalence of major depression and comorbid substance use disorders in the United States between 1991-1992 and 2001-2002. Am J Psychiatry. 163:2141–2147.
13. De Berardis D, Fornaro M, Serroni N, Campanella D, Rapini G, Olivieri L, Srinivasan V, Iasevoli F, Tomasetti C, De Bartolomeis A, et al. 2015. Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression. Int J Mol Sci. 16:1111–1130.
14. De Berardis D, Marini S, Fornaro M, Srinivasan V, Iasevoli F, Tomasetti C, Valchera A, Perna G, Quera-Salva MA, Martinotti G, et al. 2013. The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice. Int J Mol Sci. 14:12458–12483.
15. de Bodinat C, Guardiola-Lemaitre B, Mocaer E, Renard P, Munoz C, Millan MJ., 2010. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov. 9:628–642.
16. Dekker JM, Crow RS, Folsom AR, Hannan PJ, Liao D, Swenne CA, Schouten EG., 2000. Low heart rate variability in a 2-minute rhythm strip predicts risk of coronary heart disease and mortality from several causes: the ARIC Study. Atherosclerosis risk in communities. Circulation. 102:1239–1244.
17. Demyttenaere K., 2011. Agomelatine: a narrative review. Eur Neuropsychopharmacol. 21(Suppl 4):S703–S709.
18. DiMicco JA., 1987. Evidence for control of cardiac vagal tone by benzodiazepine receptors. Neuropharmacology. 26:553–559.
19. Dinas PC, Koutedakis Y, Flouris AD., 2013. Effects of active and passive tobacco cigarette smoking on heart rate variability. Int J Cardiol. 163:109–115.
20. Ellis RJ, Sollers Iii JJ, Edelstein EA, Thayer JF., 2008. Data transforms for spectral analyses of heart rate variability. Biomed Sci Instrum. 44:392–397.
21. Endicott J, Spitzer RL., 1978. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry. 35:837–844.
22. Farmer MR, Ross HF, Chowdhary S, Osman F, Townend JN, Coote JH., 2003. GABAergic mechanisms involved in the vagally mediated heart rate response to muscle contraction as revealed by studies with benzodiazepines. Clin Auton Res. 13:45–50.
23. Farmer MR, Vaile JC, Osman F, Ross HF, Townend JN, Coote JH., 1998. A central gamma-aminobutyric acid mechanism in cardiac vagal control in man revealed by studies with intravenous midazolam. Clin Sci (Lond). 95:241–248.
24. Friedman BH, Thayer JF., 1998. Autonomic balance revisited: panic anxiety and heart rate variability. J Psychosom Res. 44:133–151.
25. Furukawa TA, Streiner DL, Young LT., 2001. Is antidepressant-benzodiazepine combination therapy clinically more useful? A meta-analytic study. J Affect Disord. 65:173–177.
26. Furukawa TA, Streiner DL, Young LT., 2002. Antidepressant and benzodiazepine for major depression. Cochrane Database Syst Rev. 1:CD001026.
27. Gelenberg AJ., 2010. A review of the current guidelines for depression treatment. J Clin Psychiatry. 71:e15.
28. Girouard H, Chulak C, LeJossec M, Lamontagne D, de Champlain J., 2003. Chronic antioxidant treatment improves sympathetic functions and beta-adrenergic pathway in the spontaneously hypertensive rats. J Hypertens. 21:179–188.
29. Goldstein DS, Bentho O, Park MY, Sharabi Y., 2011. Low-frequency power of heart rate variability is not a measure of cardiac sympathetic tone but may be a measure of modulation of cardiac autonomic outflows by baroreflexes. Exp Physiol. 96:1255–1261.
30. Halaris A., 2013. Inflammation, heart disease, and depression. Curr Psychiatry Rep. 15:400.
31. Jordan D., 2005. Vagal control of the heart: central serotonergic (5-HT) mechanisms. Exp Physiol. 90:175–181.
32. Kemp AH, Brunoni AR, Santos IS, Nunes MA, Dantas EM, Carvalho de Figueiredo R, Pereira AC, Ribeiro AL, Mill JG, Andreao RV, et al. 2014. Effects of depression, anxiety, comorbidity, and antidepressants on resting-state heart rate and its variability: an ELSA-Brasil cohort baseline study. Am J Psychiatry. 171:1328–1334.
33. Kemp AH, Quintana DS, Gray MA, Felmingham KL, Brown K, Gatt JM., 2010. Impact of depression and antidepressant treatment on heart rate variability: a review and meta-analysis. Biol Psychiatry. 67:1067–1074.
34. Kuo TB, Lin T, Yang CC, Li CL, Chen CF, Chou P., 1999. Effect of aging on gender differences in neural control of heart rate. Am J Physiol. 277:H2233–H2239.
35. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH., 2000. Smoking and mental illness: a population-based prevalence study. JAMA. 284:2606–2610.
36. Licht CM, de Geus EJ, van Dyck R, Penninx BW., 2010. Longitudinal evidence for unfavorable effects of antidepressants on heart rate variability. Biol Psychiatry. 68:861–868.
37. Licht CM, de Geus EJ, Zitman FG, Hoogendijk WJ, van Dyck R, Penninx BW., 2008. Association between major depressive disorder and heart rate variability in the Netherlands Study of Depression and Anxiety (NESDA). Arch Gen Psychiatry. 65:1358–1367.
38. Liu CC, Kuo TB, Yang CC., 2003. Effects of estrogen on gender-related autonomic differences in humans. Am J Physiol Heart Circ Physiol. 285:H2188–H2193.
39. Liu YW, Tzeng NS, Yeh CB, Kuo TB, Huang SY, Chang CC, Chang HA., 2016. Reduced cardiac autonomic response to deep breathing: a heritable vulnerability trait in patients with schizophrenia and their healthy first-degree relatives. Psychiatry Res. 243:335–341.
40. Lombardi F., 2002. Clinical implications of present physiological understanding of HRV components. Card Electrophysiol Rev. 6:245–249.
41. Machado C, Estevez M, Rodriguez R, Perez-Nellar J, Chinchilla M, DeFina P, Leisman G, Carrick FR, Melillo R, Schiavi A, et al. 2014. Zolpidem arousing effect in persistent vegetative state patients: autonomic, EEG and behavioral assessment. Curr Pharm Design. 20:4185–4202.
42. Mago R, Tripathi N, Andrade C., 2014. Cardiovascular adverse effects of newer antidepressants. Expert Rev Neurother. 14:539–551.
43. Nicholson A, Kuper H, Hemingway H., 2006. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J. 27:2763–2774.
44. Nikkheslat N, Zunszain PA, Horowitz MA, Barbosa IG, Parker JA, Myint AM, Schwarz MJ, Tylee AT, Carvalho LA, Pariante CM., 2015. Insufficient glucocorticoid signaling and elevated inflammation in coronary heart disease patients with comorbid depression. Brain Behav Immun. 48:8–18.
45. Nishiyama K, Yasue H, Moriyama Y, Tsunoda R, Ogawa H, Yoshimura M, Kugiyama K., 2001. Acute effects of melatonin administration on cardiovascular autonomic regulation in healthy men. Am Heart J. 141:E9.
46. O'Regan C, Kenny RA, Cronin H, Finucane C, Kearney PM., 2014. Antidepressants strongly influence the relationship between depression and heart rate variability: findings from The Irish Longitudinal Study on Ageing (TILDA). Psychol Med. 30:1–14.
47. Pechanova O, Paulis L, Simko F., 2014. Peripheral and central effects of melatonin on blood pressure regulation. Int J Mol Sci. 15:17920–17937.
48. Pizzi C, Rutjes AW, Costa GM, Fontana F, Mezzetti A, Manzoli L., 2011. Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol. 107:972–979.
49. Quintana DS, McGregor IS, Guastella AJ, Malhi GS, Kemp AH., 2013. A meta-analysis on the impact of alcohol dependence on short-term resting-state heart rate variability: implications for cardiovascular risk. Alcohol Clin Exp Res. 37(Suppl 1):E23–E29.
50. Seldenrijk A, Vogelzangs N, Batelaan NM, Wieman I, van Schaik DJ, Penninx BJ., 2015. Depression, anxiety and 6-year risk of cardiovascular disease. J Psychosom Res. 78:123–129.
51. Sevoz-Couche C, Spyer KM, Jordan D., 2000. Inhibition of rat nucleus tractus solitarius neurones by activation of 5-HT2C receptors. Neuroreport. 11:1785–1790.
52. Steptoe A, Wikman A, Molloy GJ, Messerli-Burgy N, Kaski JC., 2013. Inflammation and symptoms of depression and anxiety in patients with acute coronary heart disease. Brain Behav Immun. 31:183–188.
53. Task. 1996. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J. 17:354–381.
54. Terhardt J, Lederbogen F, Feuerhack A, Hamann-Weber B, Gilles M, Schilling C, Lecei O, Deuschle M., 2013. Heart rate variability during antidepressant treatment with venlafaxine and mirtazapine. Clin Neuropharmacol. 36:198–202.
55. Thayer JF, Lane RD., 2000. A model of neurovisceral integration in emotion regulation and dysregulation. J Affect Disord. 61:201–216.
56. Thayer JF, Lane RD., 2007. The role of vagal function in the risk for cardiovascular disease and mortality. Biol Psychol. 74:224–242.
57. Thayer JF, Yamamoto SS, Brosschot JF., 2010. The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. Int J Cardiol. 141:122–131.
58. Valenstein M, Taylor KK, Austin K, Kales HC, McCarthy JF, Blow FC., 2004. Benzodiazepine use among depressed patients treated in mental health settings. Am J Psychiatry. 161:654–661.
59. Win NN, Fukayama H, Kohase H, Umino M., 2005. The different effects of intravenous propofol and midazolam sedation on hemodynamic and heart rate variability. Anesth Analg. 101:97–102.
60. Xiong GL, Prybol K, Boyle SH, Hall R, Streilein RD, Steffens DC, Krishnan R, Rogers JG, O'Connor CM, Jiang W, et al. 2015. Inflammation markers and major depressive disorder in patients with chronic heart failure: results from the sertraline against depression and heart disease in chronic heart failure study. Psychosom Med. 77:808–815.
61. Yeh TC, Kao LC, Tzeng NS, Kuo TB, Huang SY, Chang CC, Chang HA., 2016. Heart rate variability in major depressive disorder and after antidepressant treatment with agomelatine and paroxetine: Findings from the Taiwan Study of Depression and Anxiety (TAISDA). Prog Neuropsychopharmacol Biol Psychiatry. 64:60–67.
62. Yildiz M, Sahin B, Sahin A., 2006. Acute effects of oral melatonin administration on arterial distensibility, as determined by carotid-femoral pulse wave velocity, in healthy young men. Exp Clin Cardiol. 11:311–313.
63. Zitman FG, Couvee JE., 2001. Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper-off: report on behalf of the Dutch Chronic Benzodiazepine Working Group. Br J Psychiatry. 178:317–324.